Fig. 1: The procedure of donor-derived CD19 CAR-T cells.
From: Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
The BMCs were apheresised from sibling donor or HLA-haplotype-matched donor, then the T cells were selected and transfected with lentivirus to generate CARs. At last, the qualified CAR-T cells were infused into relapse subjects to kill the leukemia cells. CAR chimeric antigen receptor, BMC blood mononuclear cells.
